Success for Amicus, +50% for PropThink Members
Research - Success for Amicus Therapeutics (FOLD) in a study of migalastat meant +50% for PropThink subscribers who followed our trade recommendation.
Read nowMust Read
Obesity & PD-1: History Doesn’t Repeat But It Rhymes
The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical Submits 510(k) for Insulin Patch Pump
Modular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumLatest Posts
Ampio Hopes to Broaden FDA Label with Newest Ampion Data
Insights - A small and open-label study of Ampio Pharmaceuticals’ (AMPE)Â AMPIONÂ given in multiple injections demonstrated positive results at 6-weeks, said Ampio on Monday morning, producing pain reduction … Continue Reading
Read now
Another Big Week for RNAi Therapeutics
Insights - Arrowhead Research (ARWR)Â raised as many questions as it answered this week when the company reported interim results from a mid-stage study of hepatitis B drug … Continue Reading
Read now
Pharmacyclics’ Quarterly Results Support Long-Term Imbruvica Thesis
Research - OWN PCYC as Imbruvica continues to secure foothold in oncology. Cash and emerging pipeline offer options diversification for this small company. Second quarter results demonstrate continued growth … Continue Reading
Premium
Takeaways from OncoGeneX’s Second Quarter Results
Research - Takeaways from OncoGeneX's (OGXI). Knowing this could make or save you some $$.
PremiumArrowhead: All Eyes on November Medical Meeting
Insights - On Tuesday evening, Arrowhead Research (ARWR) released the first human results for its experimental therapeutic ARC-520 in hepatitis B along with its second quarter financial results. Though not … Continue Reading
Read nowIntercept Pharma Back in Favor on Updated FLINT Results
Insights - Investors are again infatuated with Intercept Pharmaceuticals (ICPT), which on Monday reported further results from a mid-stage study of drug candidate obeticholic acid. ICPT rocketed higher by 400% … Continue Reading
Read now